United Kingdom· GB-APID-41210911000001108
Tezspire 210mg/1.91ml solution for injection pre-filled syringes
A tezepelumab product containing tezepelumab, registered in United Kingdom by AstraZeneca UK Ltd. The same ATC class is registered in 16 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Tezepelumab is registered in 16 of 19 countries.
Countries holding a registration under ATC R03DX11 (tezepelumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 10 of them publish a price we can compare per daily dose
Tezepelumab · ATC R03DX11
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tezepelumab costs, country by country.
Normalised to the WHO defined daily dose (7.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tezepelumab · price per daily dose (7.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$48.28
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Tezepelumab
- Manufacturer
- AstraZeneca UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- R03DX11
- ATC class
- Tezepelumab
- Defined daily dose
- 7.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin05000456071932
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tezepelumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTEZSPIREAstraZeneca AB, Södertälje
- United StatesTEZSPIREAmgen Inc
- SwitzerlandTezspire 110 mg/ml, Injektionslösung in einem FertigpenAstraZeneca AG
- SpainTEZSPIRE 210 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAAstrazeneca Ab
- FinlandTezspireAstraZeneca AB
- FranceTEZSPIRE 210 mg, solution injectable en seringue préremplieASTRAZENECA AB
- BelgiumTezspire 210 mgAstraZeneca
- CanadaTEZSPIREASTRAZENECA CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tezspire
- Liechtenstein · Tezspire
- Norway · Tezspire
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d22e9e88-9357-4bd1-b221-aa9f28a9eb53 GET /v1/drugs/d22e9e88-9357-4bd1-b221-aa9f28a9eb53?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "41210911000001108",
"desc": "Tezspire 210mg/1.91ml solution for injection pre-filled syringes (AstraZeneca UK Ltd)",
"form": "Solution for injection",
"vpid": "41329711000001103",
"source": "dmd",
"vtm_id": "1332041008",
"strength": "110 mg",
"substance": "Tezepelumab",
"ingredient": "Tezepelumab",
"supplier_code": "3583301000001102"
}See everything about tezepelumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.